Artelo BiosciencesARTL
About: Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.
Employees: 6
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0.03% more ownership
Funds ownership: 0.77% [Q1] → 0.8% (+0.03%) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
4% less capital invested
Capital invested by funds: $37.2K [Q1] → $35.7K (-$1.54K) [Q2]
14% less funds holding
Funds holding: 7 [Q1] → 6 (-1) [Q2]
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
EF Hutton Jason Kolbert 39% 1-year accuracy 22 / 56 met price target | 380%upside $6 | Buy Initiated | 1 Oct 2024 |
HC Wainwright & Co. Vernon Bernardino 35% 1-year accuracy 9 / 26 met price target | 300%upside $5 | Buy Reiterated | 14 Aug 2024 |
